keyword
MENU ▼
Read by QxMD icon Read
search

Asfotase alfa

keyword
https://www.readbyqxmd.com/read/27699270/asfotase-alfa-therapy-for-children-with-hypophosphatasia
#1
Michael P Whyte, Katherine L Madson, Dawn Phillips, Amy L Reeves, William H McAlister, Amy Yakimoski, Karen E Mack, Kim Hamilton, Kori Kagan, Kenji P Fujita, David D Thompson, Scott Moseley, Tatjana Odrljin, Cheryl Rockman-Greenberg
Background. Hypophosphatasia (HPP) is caused by loss-of-function mutation(s) of the gene that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP). Consequently, cell-surface deficiency of TNSALP phosphohydrolase activity leads to extracellular accumulation of inorganic pyrophosphate, a natural substrate of TNSALP and inhibitor of mineralization. Children with HPP can manifest rickets, skeletal pain, deformity, fracture, muscle weakness, and premature deciduous tooth loss. Asfotase alfa is a recombinant, bone-targeted, human TNSALP injected s...
June 16, 2016: JCI Insight
https://www.readbyqxmd.com/read/27403786/asfotase-alfa-strensiq-for-hypophosphatasia
#2
(no author information available yet)
No abstract text is available yet for this article.
2016: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/27376160/asfotase-alfa-enzyme-replacement-for-the-treatment-of-bone-disease-in-hypophosphatasia
#3
REVIEW
C Hofmann, L Seefried, F Jakob
Hypophosphatasia (HPP) is a rare disease caused by loss-of-function mutations in the tissue-nonspecific alkaline phosphatase (TNAP, TNSALP) gene. HPP causes a multisystemic syndrome with a predominant bone phenotype. The clinical spectrum ranges from high lethality in early onset (<6 months) HPP to mild late-onset syndromes. HPP management so far has been only supportive. Subcutaneous asfotase alfa, a first-in-class bone-targeted human TNAP enzyme replacement therapy, is the first compound to be approved for long-term treatment of bone manifestations in pediatric-onset HPP...
May 2016: Drugs of Today
https://www.readbyqxmd.com/read/27274262/pathophysiology-of-hypophosphatasia-and-the-potential-role-of-asfotase-alfa
#4
REVIEW
Hideo Orimo
Hypophosphatasia (HPP) is an inherited systemic bone disease that is characterized by bone hypomineralization. HPP is classified into six forms according to the age of onset and severity as perinatal (lethal), perinatal benign, infantile, childhood, adult, and odontohypophosphatasia. The causative gene of the disease is the ALPL gene that encodes tissue-nonspecific alkaline phosphatase (TNAP). TNAP is expressed ubiquitously, and its physiological role is apparent in bone mineralization. A defect in bone mineralization can manifest in several ways, including rickets or osteomalacia in HPP patients...
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/26893260/hypophosphatasia-aetiology-nosology-pathogenesis-diagnosis-and-treatment
#5
REVIEW
Michael P Whyte
Hypophosphatasia is the inborn error of metabolism characterized by low serum alkaline phosphatase activity (hypophosphatasaemia). This biochemical hallmark reflects loss-of-function mutations within the gene that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP). TNSALP is a cell-surface homodimeric phosphohydrolase that is richly expressed in the skeleton, liver, kidney and developing teeth. In hypophosphatasia, extracellular accumulation of TNSALP natural substrates includes inorganic pyrophosphate, an inhibitor of mineralization, which explains the dento-osseous and arthritic complications featuring tooth loss, rickets or osteomalacia, and calcific arthopathies...
April 2016: Nature Reviews. Endocrinology
https://www.readbyqxmd.com/read/26832358/asfotase-alfa-in-perinatal-infantile-onset-and-juvenile-onset-hypophosphatasia-a-guide-to-its-use-in-the-usa
#6
Lesley J Scott
Subcutaneous asfotase alfa (Strensiq™), a first-in-class bone-targeted human recombinant tissue-nonspecific alkaline phosphatase (TNSALP) replacement therapy, is approved in the USA for the treatment of patients with perinatal/infantile- or juvenile-onset hypophosphatasia (HPP). In clinical trials, asfotase alfa was an effective and generally well tolerated treatment for perinatal/infantile- and juvenile onset-HPP through at least 3 and 5 years' treatment, respectively. Relative to untreated age-matched, juvenile-onset-HPP historical control cohorts, survival and ventilation-free survival were significantly prolonged in asfotase alfa-treated patients, consequent to preceding improvements in bone mineralization...
February 2016: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/26529632/asfotase-alfa-treatment-improves-survival-for-perinatal-and-infantile-hypophosphatasia
#7
MULTICENTER STUDY
Michael P Whyte, Cheryl Rockman-Greenberg, Keiichi Ozono, Richard Riese, Scott Moseley, Agustin Melian, David D Thompson, Nicholas Bishop, Christine Hofmann
CONTEXT: Hypophosphatasia (HPP) is an inborn error of metabolism that, in its most severe perinatal and infantile forms, results in 50-100% mortality, typically from respiratory complications. OBJECTIVES: Our objective was to better understand the effect of treatment with asfotase alfa, a first-in-class enzyme replacement therapy, on mortality in neonates and infants with severe HPP. DESIGN/SETTING: Data from patients with the perinatal and infantile forms of HPP in two ongoing, multicenter, multinational, open-label, phase 2 interventional studies of asfotase alfa treatment were compared with data from similar patients from a retrospective natural history study...
January 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/26459154/lethal-hypophosphatasia-successfully-treated-with-enzyme-replacement-from-day-1-after-birth
#8
Yoko Okazaki, Hiroyuki Kitajima, Narutaka Mochizuki, Taichi Kitaoka, Toshimi Michigami, Keiichi Ozono
UNLABELLED: Hypophosphatasia (HPP) is a rare metabolic bone disease caused by loss-of-function mutations in the gene ALPL encoding the tissue nonspecific alkaline phosphatase (TNSALP). There is a broad range of severity in the phenotype of HPP, and the most severe form exhibits perinatal lethality without mineralization of the skeleton. Here, we describe a female infant with perinatal lethal HPP diagnosed in utero. She was treated with a recombinant ALP (asfotase alfa) as an enzyme replacement therapy (ERT), which started from 1 day after birth...
March 2016: European Journal of Pediatrics
https://www.readbyqxmd.com/read/25959417/enzyme-replacement-for-craniofacial-skeletal-defects-and-craniosynostosis-in-murine-hypophosphatasia
#9
Jin Liu, Cassie Campbell, Hwa Kyung Nam, Alexandre Caron, Manisha C Yadav, José Luis Millán, Nan E Hatch
Hypophosphatasia (HPP) is an inborn-error-of-metabolism disorder characterized by deficient bone and tooth mineralization due to loss-of function mutations in the gene (Alpl) encoding tissue-nonspecific alkaline phosphatase (TNAP). Alpl(-/-) mice exhibit many characteristics seen in infantile HPP including long bone and tooth defects, vitamin B6 responsive seizures and craniosynostosis. Previous reports demonstrated that a mineral-targeted form of TNAP rescues long bone, vertebral and tooth mineralization defects in Alpl(-/-) mice...
September 2015: Bone
https://www.readbyqxmd.com/read/25254037/hypophosphatasia-pathophysiology-and-treatment
#10
José Luis Millán, Horacio Plotkin
Hypophosphatasia (HPP) is the inborn-error-of-metabolism caused by loss-of-function mutation(s) in the gene that encodes the tissue-nonspecific isozyme of alkaline phosphatase (TNAP). The disease has been classified according to patient age when the first signs and symptoms manifest; i.e., perinatal, infantile, childhood, adult HPP. Other types include odonto HPP and perinatal benign. Babies with the perinatal/infantile forms of HPP often die with severe rickets and respiratory insufficiency and sometimes hypercalcemia and vitamin B6-responsive seizures...
September 1, 2012: Actualizaciones en Osteología
https://www.readbyqxmd.com/read/24134989/hypophosphatasia-enzyme-replacement-therapy-asfotase-alfa-decreases-tnsalp-substrate-accumulation-and-improves-functional-outcomes-in-affected-adolescents-and-adults
#11
M P Whyte, P S Kishnani, C R Greenberg, K Madson, K Mack, T Weber, A Mhanni, H Plotkin, N Kreher, H Landy, Nerissa Kreher
No abstract text is available yet for this article.
2012: Bulletin du Groupèment International Pour la Recherche Scientifique en Stomatologie & Odontologie
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"